PRESS RELEASE

Wockhardt Limited
Registered Office:
D-4, MIDC, Chikalthana
Chhatrapati Sambhajinagar
431006, India
Tel.: +91-22-2653 4444
CIN: L24230MH1999PLC120720


Mumbai, Nov 2nd, 2026

Wockhardt Reports PAT of Rs. 73 Cr for Q2 FY 27 Driving Positive Momentum

FINANCIAL HIGHLIGHTS

Wockhardt Limited, the Pharmaceutical and Biotechnology major, reported its 2nd Quarter Results for Financial Year 2026-27, today.

Q2 FY 27	Growth	H1 FY 27	Growth
INR 969 Cr. Revenue	⬆ 24%	INR 1898 Cr. Revenue	⬆ 25%
INR 165 Cr. EBITDA	⬆ 3%	INR 353 Cr. EBITDA	⬆ 35%
INR 73 Cr. PBT	⬇ 20%	INR 189 Cr. PBT	⬆ >100%
Excluding Pre ZAYNICH Launch Expenses			
INR 201 Cr. EBITDA	⬆ 26%	INR 398 Cr. EBITDA	⬆ 53%
INR 109 Cr. PBT	⬆ 20%	INR 234 Cr. PBT	⬆ >100%



Wockhardt Limited
Registered Office:
D-4, MIDC, Chikalthana
Chhatrapati Sambhajinagar
431006, India
Tel.: +91-22-2653 4444
CIN: L24230MH1999PLC120720

Q2 FY27 Performance: Revenue growth of 24% compared to previous year, revenue of Rs.969 Cr in Q2 FY27 compared to Rs.782 Cr in the previous year. EBITDA of Rs.165 Cr compared to Rs.160 Cr in the previous year and EBITDA of Rs 201 Cr Excluding pre Zaynich Launch Expenses.


H1 FY27 Performance: Revenue growth of 25% compared to previous year, revenue of Rs.1898 Cr in H1 FY27 compared to Rs.1520 Cr in the previous year. EBITDA growth of 35% in EBITDA in H1 FY27 compared to previous year, EBITDA of Rs.353 Cr compared to Rs.261 Cr in the previous year and EBITDA of Rs 398 Cr Excluding pre Zaynich Launch Expenses.

Financial Performance:

Particulars	Q2 FY27	Q2 FY26	Q1 FY27	H1 FY27	H1 FY26
	Jul - Sep 2026	Jul - Sep 2025	Apr - Jun 2026	Apr - Sep 2026	Apr - Sep 2025
Total Revenue	**969**	**782**	**929**	**1,898**	**1,520**
EBITDA before R&D	**194**	**194**	**221**	**415**	**322**
EBITDA % to Sales	*20.0%*	*24.8%*	*23.8%*	*21.9%*	*21.2%*
R&D	**29**	**34**	**34**	**63**	**61**
R&D % to Sales	*3.0%*	*4.4%*	*3.6%*	*3.3%*	*4.0%*
EBITDA	**165**	**160**	**188**	**353**	**261**
EBITDA Margins %	*17.0%*	*20.5%*	*20.2%*	*18.6%*	*17.2%*
EBITDA (Excluding pre Zaynich Launch exps.)	**201**	**160**	**197**	**398**	**261**
EBITDA Margins %	*20.8%*	*20.5%*	*21.2%*	*21.0%*	*17.2%*
Exceptional Items					**(97)**
PBT	**73**	**91**	**116**	**189**	**(18)**
PBT (Excluding pre Zaynich launch exps.)	**109**	**91**	**125**	**234**	**(18)**
Profit After Tax	**73**	**82**	**107**	**180**	**(26)**
PAT Margins %	*7.5%*	*10.5%*	*11.5%*	*9.5%*	*-1.7%*

Wockhardt Limited
Registered Office:
D-4, MIDC, Chikalthana
Chhatrapati Sambhajinagar
431006, India
Tel.: +91-22-2653 4444
CIN: L24230MH1999PLC120720

Biosimilar Highlights:



- The overall Biotech operations for the quarter stood at Rs.252 crore recording a growth of 68% vs Q2 FY26. On half yearly basis the Biotech operations recorded 87% growth while delivering Rs 487 crore. This robust achievement is fuelled by our Emerging Market biotech segment growing at ~110% in H1 FY27 with accelerated business opportunities and strategic business partnerships, new deal acquisitions from our key markets like Brazil, Thailand, Egypt, Algeria and LATAM. Our India Biotech operations continues to grow at double digit pace and is poised for decent growth in the future.

- The Company's strength lies in robust and end to end well integrated Biotech infrastructure.

- We remain committed to meeting global diabetes healthcare needs and advancing our leadership in diabetes care.

Wockhardt Limited
Registered Office:
D-4, MIDC, Chikalthana
Chhatrapati Sambhajinagar
431006, India
Tel.: +91-22-2653 4444
CIN: L24230MH1999PLC120720

Business Highlights:

Region-wise Revenue Highlights:

Q1 FY27	Regions	Currency	Q2 FY27	Q2 FY26	H1 FY27	H1 FY26
	India & Emerging Market					
156	India Branded Business	INR Cr	146	136	303	265
46	India-Others	INR Cr	45	36	92	85
263	Emerging Market	INR Cr	310	204	574	374
	EU & UK					
27	UK	GBP Mn	28	27	55	54
11	Others	Euro Mn	10	10	21	17
929	**Total revenue**	**INR Cr**	**969**	**782**	**1,898**	**1,520**

- **India Branded Business** stood at Rs.146 crore in Q2 FY27 with a growth of 8% compared to the previous year. On half yearly basis the business stood at Rs.303 crore in H1 FY27 with a growth of 14% compared to the previous year. The India Business growth was aided by substantial jump in our branded operations due to performance driven by the Diabetic therapy, NCE (EMROK) and the introduction of Regenerative Derma segment.
- **UK region** stood at GBP 28 Mn in Q2 FY27 with a growth of 4% compared to the previous year. On half yearly basis the business stood at GBP 55 Mn in H1 FY27 with a growth of 2% compared to the previous year.
- **Emerging Markets region** stood at Rs.310 crore in Q2 FY27 with a growth of 52% compared to the previous year. On half yearly basis the business stood at Rs.574 crore in H1 FY27 with a growth of 54% compared to the previous year. The robust growth was driven mainly from our Biotech Insulin segment. The Latam operations contributed significant traction to the segment growth.
- **Irish region** stood at EUR 6 Mn in Q2 FY27. On half yearly basis the business stood at EUR 11 Mn in H1 FY27 with a growth of 13% compared to the previous year.

Wockhardt Limited
Registered Office:
D-4, MIDC, Chikalthana
Chhatrapati Sambhajinagar
431006, India
Tel.: +91-22-2653 4444
CIN: L24230MH1999PLC120720

New Products Launch:


- 24 Filings, 18 Approvals and 11 launches in our International Business.
- Biosimilars 2 Filing and 4 Approvals and NCE - 1 Filing & 2 Approvals.
- Approval received for EMROK O and EMROK injection in Uganda.

Novel Antibiotics:

Key Updates:

Five Novel Antibiotics from Wockhardt completed Phase 3 Clinical Trials successfully: Emrok®, Emrok O®, Miqnaf®, Zaynich® and Foviscu®.

❖ ZAYNICH®:



- **<u>Approved in US:</u>** On May 29, US FDA approved Zaynich for the treatment of cUTI including Pyelonephritis making it 1st ever India-discovery and developed drug gaining approval from US FDA.
- **<u>EMA review process:</u>** EMA review process is progressing. In response to the Marketing Authorization Application (MAA), the EMA has communicated that the submitted dossier is adequate for review for the proposed indications, including complicated urinary tract infection (cUTI), complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia/ventilator-associated pneumonia **(HAP/VAP)** and bloodstream infections (BSI).
- **<u>CDSCO approval</u>**: Approval received for Manufacturing and marketing received on August 25, 2026.

Wockhardt Limited
Registered Office:
D-4, MIDC, Chikalthana
Chhatrapati Sambhajinagar
431006, India
Tel.: +91-22-2653 4444
CIN: L24230MH1999PLC120720

❖ EMROK®/ EMROK O®:



- Growth rate of 40% vs previous year Q2 FY26 & 37% vs previous year H1 FY26.
- Continues to address critical unmet need in the treatment of difficult-to-manage Gram-positive infections, including bone and joint infections, diabetic foot infections, and pneumonia.
- On track to become the leading brands in the anti-MRSA therapy segment.

❖ MIQNAF® NAFITHROMYCIN: approved and launched in India.

- Removal of "supply condition" by DCGI – Now facililitates marketing access to wider patient population.
- Field force deployed to align with the supply condition removal for ease of drug access.
- Increasing acceptance within the clinical community owing to comprehensive coverage of pathogens and shorter course of therapy. Filling for additional indication of Upper Respiratory Tract Infections will be done in Q3/Q4 FY27.





❖ FOVISCU® (WCK 4282):

- India Phase 2 & Phase 3 Clinical Trial completed successfully. NDA Filling completed recently.
- Underwent combined Phase 2 and Phase 3 program with enrolment of 324 hospitalized cUTI and AP patients wherein more than half of the Enterobacterales isolates (51%) were ESBL-positive, and 34% of Gram negatives were resistant to cefepime, underscoring the urgent need for stronger first-line treatment options in India, where ESBL prevalence is high.
- 5th NDA Successfully filed from Wockhardt Antibiotic Discovery Program.

PRESS RELEASE

Wockhardt Limited
Registered Office:
D-4, MIDC, Chikalthana
Chhatrapati Sambhajinagar
431006, India
Tel.: +91-22-2653 4444
CIN: L24230MH1999PLC120720

Intellectual Property Update:

7 Patents were filed and 6 Patents were granted during the quarter ended Q2 FY27 and the cumulative filings till date are 3298 and the Company holds 865 patents.

About Wockhardt



Wockhardt is a research based Global Pharmaceutical and Biotech company. Wockhardt's New Drug Discovery programme has focussed on unmet need of Anti-bacterial drugs that are effective against the menace of untreatable superbugs. Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified Infectious Disease Product) for 6 of its Anti-bacterial discovery programmes – 3 of them are Gram Negative and 3 Gram Positive effective against untreatable "Superbugs". It has a comprehensive Drug Discovery team and clinical organisation.

Wockhardt is employing around ~3300 people and 27 nationalities with presence in UK, Ireland, Switzerland, France, Mexico, Russia and many other countries. It has manufacturing and research facilities in India and UK and a manufacturing facility in Ireland. Wockhardt has a significant presence in Europe and India, with 79% of its global revenues coming from international businesses.